Interactions between clozapine and Bexxar dosimetric (tositumomab)
clozapine and tositumomab (Major Drug-Drug)
CONTRAINDICATED: The use of clozapine with other potentially myelotoxic agents may increase the risk and severity of hematologic toxicity due to additive pharmacodynamic effects. Clozapine alone may cause agranulocytosis, and the risk may theoretically increase when coadministered with other myelotoxic therapy. Agents that may be significantly myelotoxic include antineoplastic drugs, some anticonvulsant and antirheumatic medications, albendazole, chloramphenicol, colchicine, dapsone, interferons, linezolid, pentamidine, procainamide, and zidovudine.
MANAGEMENT: Clozapine should not be used concomitantly with other agents having a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function.
